10/09/2025
In a landmark move for India's healthcare sector, the Indian Council of Medical Research (ICMR) has joined forces with five leading industry partners to fast-track the production and commercialization of its first indigenous multi-stage malaria vaccine, AdFalciVax. This strategic collaboration, announced at the India MedTech Expo 2025, marks a pivotal moment in the nation's fight against Plasmodium falciparum, the deadliest malaria-causing parasite.
AdFalciVax is a true 'Make in India' triumph, developed by the ICMR-Regional Medical Research Centre in Bhubaneswar. Unlike conventional single-stage vaccines, this innovative solution targets two crucial stages of the parasite's life cycle. This dual-action approach not only protects individuals from infection but also significantly minimizes its transmission within communities, offering a comprehensive shield against the disease.
The partnership with companies like Indian Immunologicals, Panacea Biotec, and Biological E will leverage their manufacturing and distribution expertise to ensure this breakthrough technology reaches the most vulnerable populations. The vaccine's remarkable stability at room temperature for over nine months also makes it a highly practical and scalable solution for a country with diverse and often challenging geographical landscapes. This initiative embodies a powerful synergy between government-led research and private enterprise, bringing India one step closer to its vision of a 'Viksit Bharat' by 2047, where affordable, high-quality, and indigenous healthcare solutions are accessible to all.
(Yantrikas healthcare, vaccine, malaria, government, research, icmr, health, solution, yantrikas healthcare)
#ᴍᴀᴋᴇɪɴɪɴᴅɪᴀ
